DepoMed, Inc. (NASDAQ: DEPO) reported Q3 EPS of ($0.15), $0.07 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $16.52 million versus the consensus estimate of $10.4 million.

Earnings